Seizure Resistance Articles & Analysis
4 news found
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell ...
“We are excited to have begun recruiting for the clinical trial and to evaluate the safety and efficacy of NRTX-1001, which has the potential to improve quality of life for people living with drug-resistant focal epilepsy. The data, generated from a single targeted administration in a preclinical model of chronic mesial temporal lobe epilepsy, demonstrate that the ...
About Neurona’s Phase 1/2 clinical trial of NRTX-1001 for MTLE Neurona’s multi-center, Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, and efficacy of a single administration of NRTX-1001 for drug-resistant mesial temporal lobe epilepsy (MTLE). The first stage of the trial is an open label dose-escalation study in up to 10 people with MTLE. ...
“These preclinical data, in a model of drug-resistant epilepsy, demonstrate that a single administration of NRTX-1001 achieves durable and significant suppression of seizures and reduction of hippocampal pathology, important metrics for the potential resolution of chronic focal-onset epilepsy. ...